In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medical Device and In Vitro Diagnostics/Research Deal Statistics Quarterly, Q2 2010

Executive Summary

Highlights from the Q1 2010 review of medical device and in vitro diagnostics/research dealmaking: With most of the funding in the form of venture rounds, medical device financing totaled $548 million in the second quarter, a 10% drop from Q1. Device acquisitions picked up, with 18 transactions completed for an aggregate $4.4 billion. Including GenMark's IPO, the first done in the sector since November 2007, in vitro diagnostic/research financing more than doubled Q1's dollar volume, reaching $364 million in the second quarter. The four IVD/Research acquisitions done in Q2 totalled $226 million.
Advertisement

Related Content

VC Investment In Diagnostics And Eyes Delivering Strongest Returns
Covidien - Back on Top: An Interview with Richard Meelia
Covidien - Back on Top: An Interview with Richard Meelia
The Shake Up At Endo Pharma
Covidien Expands Oximetry Biz With Somanetics Acquisition
Covidien Runs Familiar But Different Plays to Build Vascular Franchise
St. Jude Joins with iRhythm in Wireless Cardiac Monitoring
Covidien Runs Familiar But Different Plays to Build Vascular Franchise
Kips Bay Medical IPO Will Fund U.S. Trial Of Bypass Graft-Protecting Mesh
For Device VCs, the Eyes, Heart and Stomach Have It

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003561

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel